Updated best practice statements regarding sodium-glucose cotransporter 2 inhibitors and serum potassium levels

Am J Health Syst Pharm. 2021 Jul 22;78(15):1369-1370. doi: 10.1093/ajhp/zxab124.

Authors

Lauren G Pamulapati¹, Charmaine D Rochester-Eyeguokan², Kathleen J Pincus²

Affiliations

¹ Department of Pharmacotherapy and Outcomes Science Virginia Commonwealth University School of Pharmacy Richmond, VA, USA.
² Department of Pharmacy Practice and Science University of Maryland School of Pharmacy Baltimore, MD, USA.

PMID: 33764389
DOI: 10.1093/ajhp/zxab124

No abstract available

Keywords: SGLT-2 inhibitor; hyperkalemia; serum potassium.

Publication types

Letter
Comment

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2 / drug therapy
Humans
Hypoglycemic Agents
Potassium* / blood
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Blood Glucose
Hypoglycemic Agents
Potassium
Sodium-Glucose Transporter 2 Inhibitors